Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of Silycus in Cushing's disease
2020-005605-93Phase 2Active
- Sponsor
- IBI Lorenzini
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of silibinin in Corticotropin adenoma (ACTHoma), sponsored by IBI Lorenzini. Primary endpoint: Primary efficacy: reduction/normalization of cortisol. Started Oct 2021; status: active.
02
Drugs
silibinin
03
Conditions
Corticotropin adenoma (ACTHoma)
Beyond the preview
Go deeper on 2020-005605-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005605-93.